The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Capivasertib (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms STAKT
- 13 Dec 2019 Primary endpoint has been met. (Pharmacodynamic biomarker analysis in tumour tissue to assess the biological effect of AZD5363 on markers of anti-proliferation and the AKT pathway)
- 13 Dec 2019 Results published in the Clinical Cancer Research
- 09 Dec 2017 Results examined whether AZD5363 impacts on key biomarkers within the AKT pathway and their subsequent effects on Ki67, a marker of tumor proliferation, were presented at the 40th Annual San Antonio Breast Cancer Symposium.